Business
from24/7 Wall St.
2 weeks agoEli Lilly Falls 5% - FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares
Eli Lilly stock fell 5% amid FDA decision uncertainty on its oral obesity pill orforglipron, competitive pressure from Novo Nordisk's oral GLP-1 offerings, and concerns about compounded tirzepatide products.